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Introduction
Idiopathic rapid eye movement (REM) sleep behavioural
disorder (RBD) is classified as one of the REM parasom-
nias with clinical characteristics including unpleasant
dreams, acting out of dreams, and loss of the typical muscle
atonia during the REM phase of sleep. Other associated
clinical features include olfactory loss, dysautonomia,
colour vision impairment and subtle Parkinsonian signs.
RBD has been shown to predict development of an alpha-
synucleinopathy in 20–45 % of patients within 5 years, and
up to 92 % within 14 years post-diagnosis. Hence, this
disorder provides a potential opportunity for understanding
the prodromal stages of the synucleinopathies and explor-
ing efficacy of potential neuroprotective agents.
Idiopathic rapid eye movement sleep behaviour
disorder: diagnosis, management, and the need
for neuroprotective interventions
Iranzo and colleagues provide a concise and readable
overview of a clinical area not often familiar to the general
neurologist. Their dissection of the disorder into its epi-
demiology, clinical features and useful research-based
questionnaires, alongside the highly relevant and pragmatic
diagnostic criteria, differential diagnosis and ‘information
to share with the patient’ make this an excellent point to
begin reappraising this subject.
Although the exact prevalence of RBD is unknown,
consensus opinion suggests that it is under-reported and
under-recognised amongst the general population. Ques-
tionnaire-based studies in elderly populations
(60–97 years) have estimated the rate to be 4.6–7.7 %,
whilst polysomnographic studies have produced values of
0.3–1.15 %. Gender appears to be a factor, with[70 % of
those diagnosed at specialist sleep units being men,
although there is some suggestion that women experience
milder symptoms and are, therefore, less likely to seek
medical attention.
At its core, RBD involves abnormal sleep behaviours
and unpleasant dreams. This review highlights the impor-
tance of a collateral history from a bed partner wherever
possible. Description of sleep-related activity tends to be
one of aggression and fear, beginning abruptly, lasting
seconds to minutes, eyes remaining closed and tending to
be confined to the bed. If the patient is woken during an
event, they tend to be easily orientated and may not recall
the nightmare. Injuries to the bed partner and/or patient are
not infrequently reported, with protective measures
including sleeping in separate rooms to moving furniture
away from the bedside. Once started, the clinical course is
variable and includes both remission and progression.
Accurate diagnosis of RBD is essential, given the
potential neurodegenerative implications discussed below.
Polysomnography, ideally with concurrent audio–visual
recording, forms the gold standard in diagnostic testing.
However, this is rarely offered as a routine form of
investigation, is expensive and requires trained specialists.
Several questionnaires have been developed, principally
the RBD screening questionnaire and RBD single–question
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screen, both demonstrating high sensitivity but limited
specificity at a population level.
It is important to highlight that there are no estab-
lished guidelines for the treatment of RBD, but that
management strategies should focus on reducing the
symptoms, discussion of the risk of phenoconversion to
one of the synucleinopathies and appropriate clinical
follow-up. Symptom management aims to reduce the
frequency and intensity of the sleep behaviours either by
removal of potentially exacerbating drugs, such as anti-
depressants and beta-blockers or instigation of treatment.
Anecdotal evidence suggests that clonazepam and
melatonin are the most effective, reducing the frequency
and intensity of symptoms, although neither of them
slows or prevents the onset of further neurodegenerative
symptoms.
Sharing of information related to the risk of phenocon-
version to a neurodegenerative disorder remains contro-
versial, not least due to the \100 % conversion rate,
difficulty in predicting the onset of symptoms and the
absence of disease-modifying or curative treatments.
However, this review supports the full discussion of
potential future symptomatology, highlighting the ease of
access to information on the internet and from other
sources. The best approach to follow-up of patients with
RBD remains uncertain, with access likely to be limited by
local availability of resources. Options include discussing
potential future symptoms with patients and asking them to
contact the department should they develop these, or to
provide follow-up appointments to assess for evidence of
motor or non-motor symptoms.
Iranzo et al. Lancet Neurol. 2016;15:405–19.
Visual short-term memory deficits in REM sleep
behaviour disorder mirror those in Parkinson’s
disease
One of the principal aims of any future neuroprotective
treatment would be to delay or prevent the development of
cognitive deficits. To allow development testing methods
that might enable an early identification of ‘at risk’ indi-
viduals, studies have targeted higher risk groups, such as
those with GBA mutations and idiopathic RBD. Previous
cognitive studies have used techniques relying on binary
responses, often not allowing the determination of the
source of error resulting in a poorer performance. This
study used a visual short-term memory (VSTM) task,
previously used in GBA mutation-positive cohorts, to
investigate the precision with which patients with RBD
retained items, and whether similar patterns of impairment
are seen with GBA mutation-negative patients with
Parkinson’s disease (PD).
This study included a total of 73 participants: 21
polysomnography-confirmed RBD, 15 drug-naı¨ve PD
patients, 11 PD patients receiving oral medical therapy and
26 age and educationally matched healthy controls. All had
normal or normal corrected vision, and all patients were
GBA mutation-negative. All participants were asked to
remember a sequence of four coloured bars in different
orientation. A single coloured bar would then appear on the
screen, and they would be asked to rotate the image to
match the original sequence. A series of additional tasks
were performed to control for reduced dexterity, temporal
decay of information and attention filtering.
Overall, RBD patients demonstrated a similar perfor-
mance to the GBA mutation-negative PD cohort with a
significantly lower overall performance (p = 0.025 and
p = 0.003, respectively) and, specifically, a higher pro-
portion of random responses (p = 0.001 and p = 0.024)
compared to controls. The authors suggested that these
results potentially reflected that both cohorts shared the
same underlying memory impairment and postulated that
disruption to cholinergic or dopaminergic neurotransmis-
sion was central to this process. However, the most excit-
ing component of this publication is its potential
applicability. The authors highlight that the results from the
RBD cohort mirror those of GBA mutation-negative idio-
pathic PD patients, unlike the higher rate of misbinding
errors seen in GBA mutation-positive cohorts. This would
imply that patients with RBD form a group which is more
representative of the more typical forms of idiopathic PD,
and could form the basis for testing of disease-modifying
treatments in future clinical trials.
Rolinski et al. Brain 2016;139:47–53.
The coeruleus/subcoeruleus complex in idiopathic
rapid eye movement sleep behaviour disorder
Published in the same edition as the previous article,
Ehrminger and colleagues set out to identify the central
neuroanatomical regions in RBD pathogenesis, as well as a
potential diagnostic test with utility on an individual patient
basis. Collectively, the locus coeruleus and subcoeruleus
form an adjacent complex, thought to be involved early in
the Braak staging of alpha-synuclein disease in human
brains. This group had already shown a reduction in neu-
romelanin signal, proportional to the loss of muscle atonia
during REM sleep using a similar imaging modality when
comparing PD patients with RBD to healthy controls.
Twenty-one patients with RBD were compared to an
equal number of age- and gender-matched controls. Each
underwent an assessment of motor, cognitive, sensory and
autonomic systems, and questionnaires were used to assess
RBD-type symptoms. Cerebral imaging involved 3 T MRI
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head T1-weighted neuromelanin-sensitive images, anal-
ysed by dividing the coeruleus/subcoeruleus complex into
three regions, the most rostral acting as a reference point
and the other two corresponding to the bilateral regions.
Two neuroradiologists, blinded to the clinical findings of
the participant, compared the intensity of ten connected
voxels from each of the bilateral regions and compared
them to the reference region. They were asked to rate each
as demonstrating: bilateral complex signal present, signal
possibly present or signal low/absent.
Overall, neuromelanin-sensitive intensities were
decreased in patients compared to controls, with individual
signal reductions demonstrating an 82.5 % sensitivity,
81 % specificity and 80.4 % positive predictive value.
Signal intensity was negatively correlated with the per-
centage of REM sleep without atonia and positively cor-
related with RBD symptom severity and sleep quality
score. The degree of signal loss in this cohort was com-
parable to that seen in PD patients with RBD symptoms,
with similar correlations between signal loss and loss of
muscle atonia during REM sleep in both groups
(r = -0.44 RBD, r = -0.49 PD with RBD cohort). The
authors suggested that these findings supported a progres-
sive dysfunction of the system involved in REM atonia and
directly linked to the clinical severity of RBD.
Results from this study, other in vivo imaging work
demonstrating changes to diffusion metrics in the midbrain
and rostral pons and post-mortem evidence of early
involvement of this region with alpha-synuclein deposition
suggest that this region is pivotal in the development of
RBD symptomatology. The authors acknowledge that this
imaging focuses on the combined coeruleus/subcoeruleus
complex, with the noradrenergic arousal system contained
in the former. This technique does not facilitate the dis-
section of exact anatomical or neuron-type involved in the
process, and it remains a possibility that there is co-de-
generation of the noradrenergic neurons. Clearly, further
longitudinal studies need to be undertaken to fully under-
stand any potential progressive change in the imaging
characteristics of this region. However, the potential of a
both sensitive and specific, individual patient, non-invasive
testing method that could be used early in the disease
process, provides huge potential not only in neuroprotec-
tive intervention but also as an outcome marker in moni-
toring progress in future clinical trials.
Ehrminger et al. Brain 2016;139:1180–88.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
1680 J Neurol (2016) 263:1678–1680
123
